Real-World data reveals how two drug combos stack up against melanoma
NCT ID NCT07091695
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 100 adults with stage III melanoma that could be removed by surgery. Researchers compared two immunotherapy drug combinations given before surgery: nivolumab plus relatlimab versus nivolumab plus ipilimumab. The goal was to understand patient characteristics, treatment patterns, and outcomes like survival and tumor response in real-world settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nivolumab + relatlimab or nivolumab + ipilimumab (immunotherapy drugs)
What this could lead to
If successful, this could help doctors understand which drug combination works better for melanoma patients before surgery, potentially improving treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors other than the drugs. It also only looks back at past data, so it cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cardinal Health
Dublin, Ohio, 43017, United States